816 related articles for article (PubMed ID: 20541699)
1. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.
Andersen RJ; Mawji NR; Wang J; Wang G; Haile S; Myung JK; Watt K; Tam T; Yang YC; Bañuelos CA; Williams DE; McEwan IJ; Wang Y; Sadar MD
Cancer Cell; 2010 Jun; 17(6):535-46. PubMed ID: 20541699
[TBL] [Abstract][Full Text] [Related]
2. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
3. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
4. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
5. Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
Banuelos CA; Tavakoli I; Tien AH; Caley DP; Mawji NR; Li Z; Wang J; Yang YC; Imamura Y; Yan L; Wen JG; Andersen RJ; Sadar MD
J Biol Chem; 2016 Oct; 291(42):22231-22243. PubMed ID: 27576691
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
7. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
8. EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor.
De Mol E; Fenwick RB; Phang CT; Buzón V; Szulc E; de la Fuente A; Escobedo A; García J; Bertoncini CW; Estébanez-Perpiñá E; McEwan IJ; Riera A; Salvatella X
ACS Chem Biol; 2016 Sep; 11(9):2499-505. PubMed ID: 27356095
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
11. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
Brand LJ; Olson ME; Ravindranathan P; Guo H; Kempema AM; Andrews TE; Chen X; Raj GV; Harki DA; Dehm SM
Oncotarget; 2015 Feb; 6(6):3811-24. PubMed ID: 25669987
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
13. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
[TBL] [Abstract][Full Text] [Related]
14. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
15. Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Banuelos CA; Lal A; Tien AH; Shah N; Yang YC; Mawji NR; Meimetis LG; Park J; Kunzhong J; Andersen RJ; Sadar MD
PLoS One; 2014; 9(9):e107991. PubMed ID: 25268119
[TBL] [Abstract][Full Text] [Related]
16. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
17. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
18. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
[TBL] [Abstract][Full Text] [Related]
19. Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.
Zhao K; Li S; Wu L; Lai C; Yang G
J Biol Chem; 2014 Jul; 289(30):20824-35. PubMed ID: 24942741
[TBL] [Abstract][Full Text] [Related]
20. Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain.
Peng S; Wang J; Chen H; Hu P; He XL; He Y; Wang M; Tang W; He Q; Wang YY; Xie J; Guo D; Ren S; Liu M; Qiu WW; Yi Z
Cell Biol Toxicol; 2020 Oct; 36(5):399-416. PubMed ID: 32002708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
